Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2021

Collaborative Arrangements [Abstract]

Summarized financial information related to this collaboration is as follows:


Years Ended December 31	2021		2020		2019
Alliance revenue - Lynparza	$	989	$	725	$	444
Alliance revenue - Koselugo	29		8		—
Total alliance revenue	$	1,018	$	733	$	444

Cost of sales (1)	167		247		148
Selling, general and administrative	178		160		138
Research and development	120		133		168

December 31	2021		2020
Receivables from AstraZeneca included in Other current assets	$	271	$	215
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2)	415		423

(1) Represents amortization of capitalized milestone payments.

(2) Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:


Years Ended December 31	2021		2020		2019
Alliance revenue - Lenvima	$	704	$	580	$	404

Cost of sales (1)	195		271		206
Selling, general and administrative	127		73		80
Research and development	173		185		189

December 31	2021		2020
Receivables from Eisai included in Other current assets	$	200	$	157
Payables to Eisai included in Accrued and other current liabilities (2)	625		335
Payables to Eisai included in Other Noncurrent Liabilities (3)	—		600

(1) Represents amortization of capitalized milestone payments.

(2) Includes accrued milestone and future option payments.

(3) Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:


Years Ended December 31	2021		2020		2019
Alliance revenue - Adempas/Verquvo	$	342	$	281	$	204
Net sales of Adempas recorded by Merck	252		220		215
Net sales of Verquvo recorded by Merck	7		—		—
Total sales	$	601	$	501	$	419

Cost of sales (1)	424		196		188
Selling, general and administrative	126		47		34
Research and development	53		63		126

December 31	2021		2020
Receivables from Bayer included in Other current assets	$	114	$	65
Payables to Bayer included in Accrued and other current Liabilities (2)	472		—

(1) Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense as noted above. In addition, cost of sales in all periods now includes Bayer’s share of profits from sales in Merck’s marketing territories.

(2) Includes accrued milestone payment.

Summarized financial information related to this collaboration is as follows:


Years Ended December 31	2021		2020
Molnupiravir sales	$	952	$	—

Cost of sales (1)	494		13
Selling, general and administrative	33		6
Research and development (2)	60		323

December 31	2021		2020
Payables to Ridgeback included in Accrued and other current liabilities (3)	$	283	$	3

(1) Includes royalty expense and amortization of capitalized milestone payments.

(2) Amount in 2020 includes upfront payment.

(3) Includes accrued royalty and milestone payments.